573 related articles for article (PubMed ID: 35676838)
1. The Therapeutic Benefits of Intravenously Administrated Nanoparticles in Stroke and Age-related Neurodegenerative Diseases.
Farhoudi M; Sadigh-Eteghad S; Mahmoudi J; Farjami A; Mahmoudian M; Salatin S
Curr Pharm Des; 2022; 28(24):1985-2000. PubMed ID: 35676838
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases.
Saraiva C; Praça C; Ferreira R; Santos T; Ferreira L; Bernardino L
J Control Release; 2016 Aug; 235():34-47. PubMed ID: 27208862
[TBL] [Abstract][Full Text] [Related]
3. Application of Nano-based Drug Loading Systems in the Treatment of Neurological Infections: An Updated Review.
Sadigh-Eteghad S; Shahi S; Mahmoudi J; Farjami A; Bazmani A; Naghili B; Dizaj SM; Salatin S
Curr Pharm Des; 2022; 28(28):2330-2342. PubMed ID: 35909277
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.
Sim TM; Tarini D; Dheen ST; Bay BH; Srinivasan DK
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842530
[TBL] [Abstract][Full Text] [Related]
5. Cell-Penetrating Peptides: Promising Therapeutics and Drug-Delivery Systems for Neurodegenerative Diseases.
Pirhaghi M; Mamashli F; Moosavi-Movahedi F; Arghavani P; Amiri A; Davaeil B; Mohammad-Zaheri M; Mousavi-Jarrahi Z; Sharma D; Langel Ü; Otzen DE; Saboury AA
Mol Pharm; 2024 May; 21(5):2097-2117. PubMed ID: 38440998
[TBL] [Abstract][Full Text] [Related]
6. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.
Hanson LR; Frey WH
BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S5. PubMed ID: 19091002
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's Disease and Parkinson's Disease: A Review of Current Treatment Adopting a Nanotechnology Approach.
Trompetero A; Gordillo A; Del Pilar MC; Cristina VM; Bustos Cruz RH
Curr Pharm Des; 2018; 24(1):22-45. PubMed ID: 28847307
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?
Pinheiro RGR; Coutinho AJ; Pinheiro M; Neves AR
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769082
[TBL] [Abstract][Full Text] [Related]
9. Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles-Focus on Alzheimer's and Parkinson's disease.
Hernando S; Santos-Vizcaíno E; Igartua M; Hernandez RM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1898. PubMed ID: 37157144
[TBL] [Abstract][Full Text] [Related]
10. Research Progress of Nanocarriers for the Treatment of Alzheimer's Disease.
Li L; Zhang J; Huang X; Du J; Tu Z; Wu H; Liu X; Yuan M
Curr Pharm Des; 2023; 29(2):95-115. PubMed ID: 36529920
[TBL] [Abstract][Full Text] [Related]
11. Polyphenols and Their Impact on the Prevention of Neurodegenerative Diseases and Development.
Grabska-Kobyłecka I; Szpakowski P; Król A; Książek-Winiarek D; Kobyłecki A; Głąbiński A; Nowak D
Nutrients; 2023 Aug; 15(15):. PubMed ID: 37571391
[TBL] [Abstract][Full Text] [Related]
12. Brain Targeting Nanomedicines: Pitfalls and Promise.
Kakinen A; Jiang Y; Davis TP; Teesalu T; Saarma M
Int J Nanomedicine; 2024; 19():4857-4875. PubMed ID: 38828195
[TBL] [Abstract][Full Text] [Related]
13. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.
Loureiro JA; Gomes B; Coelho MA; do Carmo Pereira M; Rocha S
Nanomedicine (Lond); 2014 Apr; 9(5):709-22. PubMed ID: 24827845
[TBL] [Abstract][Full Text] [Related]
14. Current Limitations in the Treatment of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers.
Tonda-Turo C; Origlia N; Mattu C; Accorroni A; Chiono V
Curr Med Chem; 2018; 25(41):5755-5771. PubMed ID: 29473493
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicine against Alzheimer's and Parkinson's Disease.
Tandon A; Singh SJ; Chaturvedi RK
Curr Pharm Des; 2021; 27(12):1507-1545. PubMed ID: 33087025
[TBL] [Abstract][Full Text] [Related]
16. Development of Polymeric Nanoparticles for Blood-Brain Barrier Transfer-Strategies and Challenges.
Zhang W; Mehta A; Tong Z; Esser L; Voelcker NH
Adv Sci (Weinh); 2021 May; 8(10):2003937. PubMed ID: 34026447
[TBL] [Abstract][Full Text] [Related]
17. An Antisense Oligonucleotide-Loaded Blood-Brain Barrier Penetrable Nanoparticle Mediating Recruitment of Endogenous Neural Stem Cells for the Treatment of Parkinson's Disease.
Sun Y; Kong J; Ge X; Mao M; Yu H; Wang Y
ACS Nano; 2023 Mar; 17(5):4414-4432. PubMed ID: 36688425
[TBL] [Abstract][Full Text] [Related]
18. A Review on Chitosan in Drug Delivery for Treatment of Neurological and Psychiatric Disorders.
Shayganfard M
Curr Pharm Biotechnol; 2022; 23(4):538-551. PubMed ID: 34161209
[TBL] [Abstract][Full Text] [Related]
19. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy.
Desai BS; Monahan AJ; Carvey PM; Hendey B
Cell Transplant; 2007; 16(3):285-99. PubMed ID: 17503739
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems.
Cunha S; Amaral MH; Lobo JM; Silva AC
Curr Med Chem; 2016; 23(31):3618-3631. PubMed ID: 27554805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
